Veracyte, Inc. (VCYT) — Stock Valuation & Research

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte,…

VCYT key statistics

Price$40.08
Market cap$3.2B
SectorHealthcare
IndustryMedical - Diagnostics & Research
ExchangeNASDAQ
52-week range29.455-60.91
Beta1.93

Explore VCYT's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.